September Member News Highlights

Alexion Pharmaceuticals, Inc., Cheshire has announced the European Commission’s approval of  Strensiq™, a long-term enzyme replacement therapy that is the first treatment to be approved for treating pediatric-onset hypophosphatasia (HPP), a life-threatening rare disease affecting bone conditions including rickets/osteomalacia, altered calcium and phosphate metabolism, impaired growth and mobility, respiratory compromise and vitamin B6-responsive seizures. Alexion expects to begin serving patients in Germany in October. Regulatory decisions in the U.S. are expected in the second half of 2015.

Ironwood Capital, Avon, has named President Marc A. Reich Chairman and CEO. Reich will focus on firm management and strategy, investor relations and raising capital. Ironwood’s chief investment officer, Carolyn C. Galiette, will become President, keeping her previous title and duties as Senior Managing Director. Ironwood has more than $500 million under management, and is implementing these changes as part of a long-standing succession plan. Managing Director Victor R. Budnick, previously President and Executive Director of quasi-public venture capital entity, Connecticut Innovations, adds ‘senior’ to his title.

 

Leave a Reply